Found 389 results in Expert Content

Summary: Learn more about orally disintegrating tablets as a solution to various factors that impact treatment adherence rates across various diseases.

Summary: Learn more about developing intranasal products, advantages of intranasal vaccines & the considerations and challenges associated with this delivery route.

Read this case study to learn more about Catalent's partnership with Clarus to develop a unique and convenient drug delivery form for their hormone replacement therapy.

Summary: Experts discuss integrated solutions in the pharmaceutical industry and the benefits and challenges of this approach. Is this the key to more aggressive development milestones?

Summary: Listen in as Mike and Darren share how new modalities and manufacturing technologies have altered the partnership landscape between developers and CDMOs.

Summary: This article explores the needs of different patient groups, identifies frequent issues leading to non-compliance, looks at the role of orally disintegrating tablets (ODTs) in helping improve patient compliance, and provides examples of improving the delivery profile of the drug.

Summary: Listen in as experts Sherief Shaaban from Catalent and Kurt von Emster of Abingworth discuss taking a drug from concept to a tangible solution with a renewed focus on milestones, timelines, and efficiencies. Learn how biotechs are reconsidering strategic partnerships to better navigate development pathways, accelerate timelines, avoid common pitfalls, and stretch limited capital further than before.

Summary: This executive summary explores the rationale for intranasal drug delivery and the key intranasal drug product formulation design and optimization considerations that can help ensure safe and effective product performance and manufacturability.​

Summary: This article examines critical aspects of formulation development for spray-dried powders and the risk mitigation strategies that may be applied to address a range of common issues during production.

Learn how to accelerate and de-risk clinical-stage drug programs by understanding phase-appropriate strategies that can give your molecule the best chance for success!